2. Search Result
Search Result
Results for "

cardiac action potential duration

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

1

Natural
Products

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112879
    Mito-TEMPO
    Maximum Cited Publications
    164 Publications Verification

    		 Calcium Channel PINK1/Parkin Mitochondrial Metabolism Apoptosis Autophagy NOD-like Receptor (NLR) Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Mito-TEMPO is a mitochondria-targeted antioxidant. Mito-TEMPO induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. Mito-TEMPO regulates Ca 2+ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. Mito-TEMPO reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. Mito-TEMPO can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke .
    Mito-TEMPO
  • HY-17504
    Rosuvastatin Calcium
    20+ Cited Publications

    Rosuvastatin hemicalcium; ZD 4522 Calcium

    		 HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin Calcium
  • HY-17504A
    Rosuvastatin
    20+ Cited Publications

    ZD 4522

    		 HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin
  • HY-17504B
    Rosuvastatin Sodium
    20+ Cited Publications

    ZD 4522 Sodium; X-Plended Sodium; Crestor Sodium

    		 HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Bacterial Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin Sodium
  • HY-12533
    Disopyramide
    2 Publications Verification

    Dicorantil; SC-7031

    		 Sodium Channel Potassium Channel Cardiovascular Disease
    Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide
  • HY-125944
    MitoTEMPO hydrate
    Maximum Cited Publications
    164 Publications Verification

    		 Mitochondrial Metabolism PINK1/Parkin NOD-like Receptor (NLR) Autophagy Calcium Channel Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology
    MitoTEMPO hydrate is a mitochondria-targeted antioxidant . MitoTEMPO hydrate induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. MitoTEMPO hydrate regulates Ca 2+ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. MitoTEMPO hydrate reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. MitoTEMPO hydrate can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke .
    MitoTEMPO hydrate
  • HY-B1194
    Tetramisole hydrochloride

    (±)-Tetramisole hydrochloride; DL-Tetramisole hydrochloride; R-829

    		 Potassium Channel Parasite PKA Infection Cardiovascular Disease
    Tetramisole hydrochloride is an orally active, selective inward rectifier potassium channel agonist with an EC50 of approximately 30 μM for the Kir2.1 subunit. Tetramisole hydrochloride is also an anti-nematode agent that blocks neuromuscular transmission by non-competitive depolarization. Tetramisole hydrochloride promotes the forward transport of Kir2.1 channels, hyperpolarizes the resting potential (RP), shortens the action potential duration (APD), inhibits intracellular calcium overload and the PKA signaling pathway, and exerts anti-arrhythmic and anti-myocardial remodeling activities. Tetramisole hydrochloride can be used in cardiac electrophysiology research and research related to myocardial ischemia and heart failure .
    Tetramisole hydrochloride
  • HY-12533A
    Disopyramide phosphate
    2 Publications Verification

    Dicorantil phosphate; SC-7031 phosphate

    		 Potassium Channel Sodium Channel Cardiovascular Disease
    Disopyramide phosphate is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide phosphate blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide phosphate inhibits HERG encoded potassium channels. Disopyramide phosphate also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide phosphate
  • HY-108591
    L-364,373

    R-L3

    		 Potassium Channel Cardiovascular Disease
    L-364,373 (R-L3) is a voltage-gated Kv7.1 (KCNQ1)/mink channels activator. L-364,373 activates Iks (slow delayed rectifier potassium current) and shortens action potential duration in guinea pig cardiac myocytes, and suppresses early afterdepolarizations in rabbit ventricular myocytes .
    L-364,373
  • HY-124702
    ICA-105574
    1 Publications Verification

    		 Potassium Channel Cardiovascular Disease
    ICA-105574 is a potent and efficacious hERG channel activator. The primary mechanism by which ICA-105574 potentiates hERG channel activity is by removing hERG channel inactivation. ICA-105574 steeply potentiates current amplitudes more than 10-fold with an EC50 value of 0.5 +/- 0.1 μM and a Hill slope (n(H)) of 3.3 +/- 0.2. ICA-105574 can prevent arrhythmias induced by cardiac delayed repolarization. ICA-105574 shortens action potential duration in ventricular myocytes concentration-dependently .
    ICA-105574
  • HY-W779529
    Cerberin

    2'-Acetylneriifolin

    		 Na+/K+ ATPase Cancer
    Cerberin is a cardiac glycoside that has been found in C. odollam and has cytotoxic and cardiac modulatory activities. It is cytotoxic to KB and NCI H187 cancer cells (IC50s=1.92 and 1.24 μg/mL).1 Cerberin inhibits Na+/K+-ATPase, increasing intracellular sodium levels and action potential duration in cardiac cells.
    Cerberin
  • HY-126028A
    (+)-Sotalol

    (S)-Sotalol

    		 Adrenergic Receptor Cardiovascular Disease Neurological Disease
    (+)-Sotalol ((S)-Sotalol) is the S-isomer of Sotalol (HY-103196). Sotalol is an orally active, non-selective β-adrenergic receptor blocker. (+)-Sotalol is an antiarrhythmic agent. (+)-Sotalol can prolong action potential duration in isolated cardiac muscle .
    (+)-Sotalol
  • HY-119747
    WAY-123223

    		Potassium Channel Cardiovascular Disease
    WAY-123223 is an orally active potassium channel (Potassium Channel) blocker. WAY-123223 prolongs the transmembrane action potential duration and cardiac refractory period of canine Purkinje fibers. In canine models, WAY-123223 increases the ventricular fibrillation threshold, restores sinus rhythm from ventricular fibrillation, and exerts antiarrhythmic effects. WAY-123223 can be used in research related to cardiovascular diseases such as arrhythmias .
    WAY-123223
  • HY-17504AS1
    Rosuvastatin-d6

    ZD 4522-d6

    		 Isotope-Labeled Compounds Autophagy Bacterial HMG-CoA Reductase (HMGCR) Potassium Channel Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin-d6 (ZD 4522-d6) is deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin-d6
  • HY-17504AS
    Rosuvastatin-d3

    ZD 4522 d3

    		 Isotope-Labeled Compounds HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Cardiovascular Disease Metabolic Disease
    Rosuvastatin-d3 (ZD 4522-d3) is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals .
    Rosuvastatin-d3
  • HY-17504BR
    Rosuvastatin Sodium (Standard)

    ZD 4522 Sodium (Standard); X-Plended Sodium (Standard); Crestor Sodium (Standard)

    		 HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Bacterial Reference Standards Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin (Sodium) (Standard) is the analytical standard of Rosuvastatin (Sodium). This product is intended for research and analytical applications. Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin Sodium (Standard)
  • HY-17504BS2
    Rosuvastatin-13C,d3 sodium

    ZD 4522-13C,d3 sodium; X-Plended-13C,d3 sodium; Crestor-13C,d3 sodium

    		 Autophagy Bacterial HMG-CoA Reductase (HMGCR) Potassium Channel Isotope-Labeled Compounds Cardiovascular Disease Metabolic Disease
    Rosuvastatin- 13C,d3 sodium is 13C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin-13C,d3 sodium
  • HY-120926
    BBR 2160

    		Calcium Channel Others
    BBR 2160 is a compound with cardiac electrophysiological effects and is a dihydropyridine calcium antagonist that can reduce myocardial contractility and action potential duration and has calcium antagonist properties.
    BBR 2160
  • HY-12533B
    Disopyramide hydrochloride

    Dicorantil hydrochloride; SC-7031 hydrochloride

    		 Sodium Channel Potassium Channel Cardiovascular Disease
    Disopyramide hydrochloride is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide hydrochloride blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide hydrochloride inhibits HERG encoded potassium channels. Disopyramide hydrochloride also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide hydrochloride
  • HY-113841
    RS-87337

    		Others Cardiovascular Disease
    RS-87337 is an orally active antiarrhythmic agent that increases the duration and the maximum rate of rise of cardiac muscle action potentials. RS-87337 is promising for research of antiarrhythmic and cardioprotective agents .
    RS-87337
  • HY-N0747R
    Oxypeucedanin (Standard)

    		Reference Standards Potassium Channel Apoptosis PI3K NF-κB Akt p38 MAPK ERK COX NO Synthase JNK Cardiovascular Disease Cancer
    Oxypeucedanin (Standard) is a furanocoumarin derivative found in Angelica dahurica. Oxypeucedanin (Standard) is an orally active PI3K/AKT/NF-κB, MAPK, and ROS inhibitor. Oxypeucedanin (Standard) induces cell cycle arrest and apoptosis. Oxypeucedanin (Standard) inhibits hKv1.5 channel currents (IC50: 76 nM). Oxypeucedanin (Standard) exhibits anticancer, anti-inflammatory, antioxidant and antiarrhythmic activities .
    Oxypeucedanin (Standard)
  • HY-12533R
    Disopyramide (Standard)

    Dicorantil (Standard); SC-7031 (Standard)

    		 Reference Standards Sodium Channel Potassium Channel Cardiovascular Disease
    Disopyramide (Standard) is the analytical standard of Disopyramide. This product is intended for research and analytical applications. Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide (Standard)
  • HY-12533AR
    Disopyramide phosphate (Standard)

    Dicorantil phosphate (Standard); SC-7031 phosphate (Standard)

    		 Potassium Channel Sodium Channel Reference Standards Cardiovascular Disease
    Disopyramide (phosphate) (Standard) is the analytical standard of Disopyramide (phosphate). This product is intended for research and analytical applications. Disopyramide phosphate is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide phosphate blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide phosphate inhibits HERG encoded potassium channels. Disopyramide phosphate also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide phosphate (Standard)
  • HY-118148
    UK-66914

    		Potassium Channel Cardiovascular Disease
    UK-66914, is a class III antiarrhythmic agent that specifically acts on the delayed rectifier potassium current (I_K). UK-66914 is designed to prolong action potential duration (APD) and increase cardiac refractory period, thereby potentially terminating the reentry mechanism in arrhythmias without affecting the serious side effects of antiarrhythmic drugs associated with other ion channels such as Na+ and Ca2+ currents .
    UK-66914
  • HY-14924
    Inakalant

    		Potassium Channel Cardiovascular Disease
    Inakalant is an atrial specific potassium channel blocker with antiarrhythmic activity. Inakalant works by selectively blocking potassium channels in heart cells, thereby prolongs the action potential duration (APD) of cardiomyocytes and increases the effective refractory period of the atria and ventricles, which helps to terminate and prevent the occurrence of arrhythmias such as atrial fibrillation (AF). Inakalant can be used in the study of arrhythmia and cardiac electrophysiology .
    Inakalant
  • HY-B1194A
    Tetramisole

    		Potassium Channel Parasite PKA Infection Cardiovascular Disease
    Tetramisole is an orally active, selective inward rectifier potassium channel agonist with an EC50 of approximately 30 μM for the Kir2.1 subunit. Tetramisole is also an anti-nematode agent that blocks neuromuscular transmission by non-competitive depolarization. Tetramisole promotes the forward transport of Kir2.1 channels, hyperpolarizes the resting potential (RP), shortens the action potential duration (APD), inhibits intracellular calcium overload and the PKA signaling pathway, and exerts anti-arrhythmic and anti-myocardial remodeling activities. Tetramisole can be used in cardiac electrophysiology research and research related to myocardial ischemia and heart failure .
    Tetramisole
  • HY-B1194R
    Tetramisole hydrochloride (Standard)

    (±)-Tetramisole hydrochloride (Standard); DL-Tetramisole hydrochloride (Standard); R-829 (Standard)

    		 Reference Standards Potassium Channel Parasite PKA Infection Cardiovascular Disease
    Tetramisole hydrochloride (Standard) is the analytical standard of Tetramisole (hydrochloride). This product is intended for research and analytical applications. Tetramisole hydrochloride is an orally active, selective inward rectifier potassium channel agonist with an EC50 of approximately 30 μM for the Kir2.1 subunit. Tetramisole hydrochloride is also an anti-nematode agent that blocks neuromuscular transmission by non-competitive depolarization. Tetramisole hydrochloride promotes the forward transport of Kir2.1 channels, hyperpolarizes the resting potential (RP), shortens the action potential duration (APD), inhibits intracellular calcium overload and the PKA signaling pathway, and exerts anti-arrhythmic and anti-myocardial remodeling activities. Tetramisole hydrochloride can be used in cardiac electrophysiology research and research related to myocardial ischemia and heart failure .
    Tetramisole hydrochloride (Standard)
  • HY-130456
    AHR 10718

    		Sodium Channel Cardiovascular Disease
    AHR 10718 is an antiarrhythmic agent that suppresses cardiac arrhythmias induced by digitalis intoxication and myocardial infarction in the intact dog. AHR 10718 also depresses membrane responsiveness and conduction, shortens the effective refractory period of specialized conducting fibers less than action potential duration .
    AHR 10718
  • HY-105439A
    Clofilium phosphate

    LY 150378

    		 Drug Derivative Cardiovascular Disease
    Clofilium phosphate (LY 150378) is an antiarrhythmic/antifibrillatory agent. Clofilium phosphate significantly prolongs the action potential duration and effective refractory period of canine cardiac Purkinje fibers, increases the ventricular fibrillation threshold, reduces the risk of reentrant arrhythmias, and enables spontaneous conversion of some ventricular fibrillation episodes to sinus rhythm. Clofilium phosphate is applicable to research related to ventricular fibrillation, arrhythmias, and ventricular tachyarrhythmias .
    Clofilium phosphate
  • HY-108591R
    L-364,373 (Standard)

    R-L3 (Standard)

    		 Reference Standards Potassium Channel Cardiovascular Disease
    L-364,373 (Standard) is the analytical standard of L-364,373 (HY-108591). This product is intended for research and analytical applications. L-364,373 (R-L3) is a voltage-gated Kv7.1 (KCNQ1)/mink channels activator. L-364,373 activates Iks (slow delayed rectifier potassium current) and shortens action potential duration in guinea pig cardiac myocytes, and suppresses early afterdepolarizations in rabbit ventricular myocytes .
    L-364,373 (Standard)
  • HY-183206
    UR 8225

    		Potassium Channel Calcium Channel Cardiovascular Disease Inflammation/Immunology
    UR 8225 is an orally active ATP-sensitive K + channel activator with vasodilator, smooth muscle relaxant, antihypertensive, and bronchodilator activities. UR 8225 induces membrane hyperpolarization by increasing outward K + conductance and reduces Ca 2+ influx through voltage-gated L-type Ca 2+ channels. UR 8225 reduces total peripheral vascular resistance, shortens cardiac action potential duration, inhibits agonist-induced Ca 2+ influx, and stimulates renin release. UR 8225 induces reflex tachycardia but lacks β-adrenergic receptor blocking activity. UR 8225 is widely applicable to research in fields related to hypertension, myocardial ischemia, ventricular fibrillation, and other conditions .
    UR 8225

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: